Pages

Monday, July 27, 2020

Fw: (LML) Surveillance of AMR in Leprosy


Leprosy Mailing List – July 27,  2020

 

Ref.:  (LML) Surveillance of AMR in Leprosy

 

From:  VV Pai, Mumbai, India


 

 

Dear Dr Schreuder and colleagues,

 

With reference to an email from Dr Rathnayake from Sri Lanka dated 30-6-2020 which I received from Dr Schreuder on 3-7-2020 regarding the plans for surveillance for AMR (anti-microbial resistance) in Sri Lanka. It is very much pertinent that research on the current scenario of drug resistance in Sri Lanka will be important and beneficial for the global surveillance programme. We have been working on projects involving field surveys and lab investigations in Mumbai.


As required find attached some key publications on this work involving the methodology of detection of gene mutations using molecular techniques. However, there are no primers available to detect mutations due to Clofazimine. Also find attached templates/links for questionnaires, consent forms, assent forms, Ethical Requisition letters. (Note editor: most of the mentioned files were not accepted by Google Group for transmission – see references).


We hope this will help in planning your proposed research work and we will be glad to help on further queries and looking forward in future endeavours.

 

https://www.who.int/ethics/review-committee/informed_consent/en/

https://uwm.edu/irb/consent-form-templates/

 

Best wishes,

Dr V V Pai

Director

Bombay Leprosy Project

 

References

-       INSTRUCTIONS FOR DRAFTING A REQUEST FOR ETHICAL REVIEW IN THE HUMANITIES AND SOCIAL AND BEHAVIOURAL SCIENCES. Harinen, Päivi. 2009.

-       Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009e15. E. Cambau et al.

-       Molecular detection of multi drug resistant Mycobacterium leprae from Indian leprosy patients.  Journal of Global Antimicrobial Resistance · October 2017

-       Study of Drug Resistance in Relapsed and New Cases of Leprosy in select rural and urban areas of Maharashtra using PCR and Mouse Footpad Assays. Vanaja Prabhakar Shetty, Dhananjaya Saranath, Anju Rajaram Dighe, Shubhada Pandya,Vivek Vasudev Pai

-       Multidrug Resistant Mycobacterium leprae from Patients with Leprosy. SHINJI MAEDA et al.

-       Surveys of knowledge and awareness of antibiotic use and antimicrobial resistance in general population: A systematic review. Hathairat Kosiyaporn et al.

-       ANTIMICROBIAL RESISTANCE IN LEPROSY. WHO REPORT OF A GLOBAL CONSULTATION. 27-28 October 2016, Kathmandu, Nepal

-       A guide for surveillance of antimicrobial resistance in leprosy. WHO, 2017 update


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/731f93f6-1928-412e-b75a-5ea49b47a3b7o%40googlegroups.com.

Friday, July 24, 2020

Fw: (LML) Questionnaire from GPZL Working Group 2


Leprosy Mailing List – July 24,  2020

 

Ref.:  (LML) Questionnaire from GPZL Working Group 2

 

From:  Alice Cruz, Quito, Ecuador


 

 

Dear friends,

 

Following the mapping of the disproportionate impact of the Covid-19 crisis among persons affected and their families and the elaboration of recommendations to the governments and non-governmental organizations, I come to ask for your kind cooperation once more. Together with the Global Partnership for Zero Leprosy we are now trying to identify the responses, or lack of it, to the humanitarian needs generated by this crisis. We need your valuable support once more to keep raising this issue among key stakeholders. Please find the message from my colleague Andie below.

 

With warm regards,

Alice

 

PORTUGUÊS


Queridxs amigxs,

 

Na sequência do mapeamento do impacto desproporcionado da Covid-19 nas pessoas afectadas e seus familiares e da elaboração de recomendações para os governos e organizações não governamentais, venho solicitar, uma vez mais, a vossa amável colaboração. Juntamente com a Parceria Global para Zero Hanseníase, estamos agora a tentar identificar as respostas, ou falta delas, às necessidades humanitárias geradas por esta crise. Precisamos do vosso apoio valioso uma vez mais para poder continuar a levantar este assunto entre as principais agências interessadas. Por favor vejam abaixo a mensagem da minha colega Andie.

 

Atentamente,

Alice

 

ESPAÑOL


Queridxs amigxs,


Después del mapeo del impacto desproporcionado de Covid-19 en las personas afectadas y sus familias y de la elaboración de recomendaciones para gobiernos y organizaciones no gubernamentales, vuelvo a pedirles, una vez más, su amable cooperación. Junto con la Alianza Global para Cero Lepra, ahora estamos tratando de identificar las respuestas, o la falta de ellas, a las necesidades humanitarias generadas por esta crisis. Necesitamos su valioso apoyo una vez más para continuar planteando este problema entre las principales agencias interesadas. Por favor, vean el mensaje de mi colega Andie a continuación.

 

Atentamente,

Alice

 

FRANÇAIS


Chers amis,

 

Suite à la cartographie de l'impact disproportionné de Covid-19 sur les personnes touchées et leurs familles et à la préparation de recommandations pour les gouvernements et les organisations non gouvernementales, je viens vous demander, une fois de plus, votre aimable collaboration. En collaboration avec le Partenariat mondial pour zéro lèpre, nous essayons à présent d'identifier les réponses, ou l'absence de réponses, aux besoins humanitaires générés par cette crise. Nous avons à nouveau besoin de votre précieux soutien pour pouvoir continuer à soulever cette question parmi les principales agences intéressées. Veuillez lire le message de mon collègue Andie ci-dessous.

 

Cordialement,

Alice

 

Message Andie Tucker

 

"Dear friends and colleagues,

I am writing on behalf of the Global Partnership for Zero Leprosy's Working Group 2 to ask for your input once more. In our last conversations we talked about the challenges facing persons affected during the COVID-19 pandemic, and your insights helped us better understand the needs of persons affected at this time. Now, we are collecting information about ways those needs are being met by governments and non-governmental organizations, to spread information about available resources, and help persons affected connect with those resources.

To gather this information we've made a brief online questionnaire that poses questions about the response of government, non-governmental organizations, and persons affected organizations to the needs of persons affected during the COVID-19 pandemic. How is your government supporting persons affected at this time? What about NGOs? Are they providing support to persons affected? What kind of support? We welcome your input on these questions. Please share your thoughts via the online form by Tuesday, 28 July: 

 

Englishhttps://forms.gle/985Y8Bgtnkeoj3hH8

Frenchhttps://forms.gle/iZ2QcU15vHcqAkBg6

Spanishhttps://forms.gle/soA57j2PMWLKGSFD8

Portuguesehttps://forms.gle/hmcf83twBZAsFGvy8

Indonesianhttps://forms.gle/Mq9ktNNh9xKadqp3A

Hindihttps://forms.gle/hjaTYj4KhtghW1YdA

Bengalihttps://forms.gle/qvUqgftqzMAjeS7p9

Nepalihttps://forms.gle/NCebM6CNqTeusEDX9

Japanese: https://forms.gle/4tmvf285pZNr2RzMA 



Thank you for sharing your perspectives with us. We will make the information collected in this questionnaire available to everyone after the conclusion of this information gathering process.
" 

 

 

Best regards, 


Andie Tucker

Project Manager 

Global Partnership for Zero Leprosy

The Task Force for Global Health

atucker@taskforce.org

678-786-7586

zeroleprosy.org


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

 

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/177cbfb5-850e-47da-b633-e515d7268efao%40googlegroups.com.

Wednesday, July 22, 2020

Fw: (LML) Transmission SARS-CoV-2

 

Leprosy Mailing List – July 22,  2020


Ref.:  (LML) Transmission SARS-CoV-2

From:  Pran Das, Birmingham, UK



Dear Pieter and colleagues,


Ben Naafs sent an interesting article about the transmission of SARS-CoV-2, Severe Acute Respiratory Syndrome coronavirus 2. A long read, but quite interesting (LML, June 10, 2020). file:///C:/Users/impie/AppData/Local/Temp/Transmission%20-%20Covid%20Reference-2.html


My thanks to Ben . His efforts must not go unnoticed. This review is going to provide me with some deep thoughts which may result into some frustrations in trying to fit in the picture of leprosy transmission and non mortal and complex evolving pathology of human leprosy.


Regards,


Pran


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

 

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/0f1782ec-2138-487a-b01c-3202b3a0a459o%40googlegroups.com.

Saturday, July 18, 2020

Fw: (LML) 6th edn of Joplings handbook of leprosy

 

 

Leprosy Mailing List – July 18,  2020

 

Ref.:  (LML) 6th edn of Joplings handbook of leprosy

 

From:  Kabir Sardana, Delhi, India


 

 

Dear Pieter,

 

 

We would like to announce the launch of 6th edn of Joplings handbook of leprosy:

Jopling's Handbook of Leprosy 6th Edn

Sardana K, Khurana A. CBS Publishers & Distributors. 2020

  

I am enclosing the sample PDF for your reference and dissemination.

 

 

 Dr Kabir Sardana 
 MD.DNB.MNAMS
 Professor 
 Dermatology 

 Dr RML Hospital & PGIMER

 Delhi-110001

 

amazon.com/author/kabir-sardana

 

 

Note editor: both PDF files were not accepted by Google Groups.

 


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

 

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/65255992-5f31-4504-a39b-77fbe6f13408o%40googlegroups.com.

Sunday, July 12, 2020

Fw: (LML) Neglect of previously treated persons & interruption of transmission

 

 

 


Leprosy Mailing List – July 12,  2020

 

Ref.:  (LML) Neglect of previously treated persons & interruption of transmission

 

From:  Joel Almeida, London and Mumbai


 

 

Dear Pieter and colleagues,

https://www.facebook.com/Morhan.Nacional/videos/288479592187469/UzpfSTE3NzQxNDA0MjI2NzgzOTY6MzA4MDQzNzM0NTM4MjAyNA/

At about 17 minutes into this conversation of people affected by Hansen's Disease (HD), a participant from India makes a startling claim.

An elderly woman with sequelae of HD survived by seeking alms. It was already a precarious existence. Owing to the lockdown, this person could not go out to seek alms. Without alms and without health care, she died. This was in Bihar, India.

Perhaps all of us need to become more methodical and effective in our efforts to show respect and care for those with sequelae of HD. Especially reaching out to those whose survival has been precarious all along.

Population-based enumeration of people with sequelae of HD would allow us to gauge the extent of need. Then we could ensure better that this person's death was not in vain. We would know of every single person with sequelae of HD at risk of premature death, or starvation, or progressive physical disability, or mental anguish, or exclusion, or reinfection, or ENL episodes, or silent neuritis, or type 1 reaction episodes etc.  We could respond more methodically, thoroughly, and effectively. No person would fall through the gaps in our well-intentioned efforts. Sometimes we have prematurely washed them out of our registers and out of our minds.

Caring for persons with sequelae is also very important for interrupting transmission. Otherwise transmission can be maintained by persons with genetically determined anergy who are left unprotected against reinfection (or endogenous relapse). Those events often are difficult to diagnose promptly. Then previously treated persons with unrecognised recurrent disease (1) can serve as sources of astronomical numbers of concentrated viable bacilli.(2) This is usually through no fault of their own. Also, growing evidence suggests that viable bacilli in such unprotected persons keep contributing to ENL episodes, type 1 reaction episodes, painful nerves and worse (3, 4, 5). That unnecessarily aggravates their suffering.

It is worth recalling some words from the powerful preamble to the Universal Declaration of Human Rights:

"Whereas disregard and contempt for human rights have resulted in barbarous acts which have outraged the conscience of mankind..."

Barbarous inaction or inadequate action or mistaken action, too, can outrage the conscience of humankind. That is because of severe consequences for people such as this woman. We could "raise our game" instead. We have the necessary good intentions and motivation. With a more methodical and better informed population-based approach, we could have consistently good outcomes too. No person with sequelae of HD need be neglected. 

 

It would be good to enumerate each person with sequelae, know where they can be reached in order to deliver competent services to them, and make the numbers of such people known loudly and widely. Then we will be better placed to raise sufficient finance, to make robust plans and train personnel sufficiently to ensure that no person with sequelae of HD is exposed to avoidable disease, destitution, or premature death. Our outcomes increasingly will match our good intentions. Interrupting transmission through competent services is demonstrably achievable outside continents with armadillos (6, 7). Ending transmission of a disease is a highly valued  prize that yields a stream of future health and financial returns. Even where there are armadillos transmission can be reduced greatly. 

Governments can be regarded as the first source of finance for public goods. However, their staff have a long list of competing priorities, including the control of high-prevalence killer diseases. Further, HD-related staff posts too often remain vacant for extended durations. That is why governments can be encouraged to channel more of their HD-related budgets to highly motivated voluntary organisations with competent personnel who are dedicated to ending the suffering, disability and persistent transmission of HD. Voluntary organisations, at least the best of them, strive constantly to "raise their game" and produce steadily improving outcomes. That typically requires specialised skills and services to be taken to the doorstep of people affected by HD. Some responsibilities can be left to government-operated general health services that often are widely distributed. However, some critical interventions in HD require specialised skills to be taken to the affected person's doorstep by skilled and mobile personnel.

Evidence suggests that by ending inadvertent (or deliberate) neglect, especially of persons with genetically determined anergy, we will hasten the end of transmission. We will have closed the critical gap in our defences against the dangerous bacilli. Otherwise, decades from now, we will probably still be wondering why children keep developing HD. This woman's death can help open our eyes (and our minds) to the room for improvement in our policies and practices.

 

The critical improvement is to end the neglect of previously treated persons who have genetically determined anergy. We are already doing much else well, but our outcomes now depend largely on this.


Joel Almeida  

 

 

Translations

 

हेंसन की बीमारी के संचरण को समाप्त करने के लिए हमें उन व्यक्तियों की उपेक्षा को समाप्त करना होगा जो पहले इलाज कर चुके हैं लेकिन आनुवंशिक रूप से बेसिली के लिए प्रतिरक्षा प्रतिक्रिया की कमी है। ऐसे व्यक्तियों में रोग की प्रारंभिक पुनरावृत्ति का निदान करना मुश्किल है। नतीजतन, एक ऐसा उपेक्षित व्यक्ति हर दिन अरबों बैक्टीरिया बहा सकता है। बेसिली के खिलाफ दीर्घकालिक संरक्षण ऐसे व्यक्तियों के लिए आवश्यक है, साथ ही बहिष्कार, विकलांगता और अत्यधिक गरीबी से सुरक्षा भी।

ब्राज़ीलियन मोरान ऑर्गेनाइजेशन की एक ऑनलाइन चर्चा से पता चला है कि हेन्सन की बीमारी की अगली कड़ी वाली महिला की भारत में कोरोनोवायरस महामारी के दौरान भुखमरी के कारण मृत्यु हो गई थी। इस तरह की दुखद घटना फिर कभी नहीं होगी, अगर हम अपनी नीतियों और प्रथाओं में सुधार करेंगे।

 

A melhoria crítica para acabar com a transmissão da hanseníase é acabar com a negligência de pessoas que foram tratadas anteriormente, mas que têm anergia que é determinada geneticamente. A recorrência da doença nessas pessoas é difícil de diagnosticar prontamente e pode resultar na disseminação de números astronômicos de bacilos viáveis a cada dia. A proteção a longo prazo contra os bacilos é necessária para essas pessoas, juntamente com a proteção contra exclusão, incapacidade e pobreza extrema.


Uma discussão on-line organizada por MORHAN revelou que uma mulher na Índia com sequelas de DH morreu de fome desde o início da endemia do COVID. Nunca mais, se melhorarmos nossas políticas e práticas.

 

 

References

 

1. Almeida J. Recurrence rate among MB patients following RFT. LML 2 June 2019 based onBalagon MF, Cellona RV, dela Cruz E et al.  Long-Term Relapse Risk of Multibacillary Leprosy after Completion of 2 Years of Multiple Drug Therapy (WHO-MDT) in Cebu, Philippines. American Journal of Tropical Medicine and Hygiene, 2009; 81, 5: 895-9

2. Davey TF, Rees RJ. The nasal discharge in leprosy: clinical and bacteriological aspects. Lepr Rev. 1974 Jun;45(2):121-34.

3. Save MP, Dighe AR, Natrajan M & Shetty VP. Association of viable Mycobacterium leprae with Type 1 reaction in leprosy. Lepr Rev (2016) 87, 78–92

4. Arora P, Sardana K, Agarwal A, Lavania M. Resistance as a cause for chronic steroid dependent ENL - a novel paradigm with potential implications in management. Lepr Rev (2019) 90, 201– 205

5. Brito MDE F, Ximenes RA, Gallo ME, BÜhrer-SÉkula S. Association between leprosy reactions after treatment and bacterial load evaluated using anti PGL-I serology and bacilloscopy. Rev Soc Bras Med Trop. 2008;41 Suppl 2:67-72.

6. Li HY, Weng XM, Li T et al. Long-Term Effect of Leprosy Control in Two Prefectures of China, 1955-1993. Int J Lepr Other Mycobact Dis. 1995 Jun;63(2):213-221.

7. Tonglet R, Pattyn SR, Nsansi BN et al. The reduction of the leprosy endemicity in northeastern Zaire 1975/1989 J.Eur J Epidemiol. 1990 Dec;6(4):404-6,

 


LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

 

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/155884c1-6628-45bc-851b-9b3376bc3251o%40googlegroups.com.

Wednesday, July 8, 2020

Fw: (LML) Infolep monthly overview of new publications on leprosy - July


Leprosy Mailing List – July 8,  2020

 

Ref.:  (LML) Infolep monthly overview of new publications on leprosy - July

 

From:  Anniek Akerboom, Amsterdam, the Netherlands


 

 

Dear colleagues,

I am pleased to share many interesting publications and WHO NTD road map webinars with you.

This week, on July 8th, you can join the WHO NTD road map webinar "How will the new NTD road map contribute to sustainable and resilient health Systems?". If you're interested you can register here. Hereby I provide you an overview of all coming WHO NTD roadmap webinars.

This month's review consists of many practical publications, such as the Policy framework for rights-based action plans from the UN Special Rapporteur on the elimination of discrimination against persons affected by leprosy and their family members and the WHO operational guidance for the COVID-19 context.

Like every month we send you an overview of publications on leprosy recently added to the Infolep website. Please feel free to contact me to receive full-text versions if these cannot be found through the Infolep portal. Also, I would be happy to assist you with literature searches.

Enjoy the read!

Kind regards,

Anniek Akerboom

Infolep Coordinator
www.leprosy-information.org
a.akerboom@infolep.org




 

 


 

Highlighted publications

 


 

Policy framework for rights-based action plans - Report of the Special Rapporteur on the elimination of discrimination against persons affected by leprosy and their family members
Cruz A. UN Human Rights Council. 2020;
Read more

Maintaining essential health services: operational guidance for the COVID-19 context
World Health Organization. 2020
Read more

Management of leprosy in the context of COVID‑19 pandemic: Recommendations by SIG leprosy (IADVL academy)
Rathod S, Suneetha S, Narang T, et al. Indian Dermatology Online Journal. 2020; 11 (3) : 345-348.
Read more

The experience of persons with disabilities with COVID-19
Stakeholder Group of Persons with Disabilities. 2020;
Read more

 


 

New publications

 


 

Comorbidities associated with non- healing of plantar ulcers in leprosy patients.
Upputuri B, Srikantam A, Mamidi R. PLoS neglected tropical diseases. 2020; 14 (6) : e0008393.
Download PDF

Response to "Three drugs are unnecessary for treating paucibacillary leprosy-A critique of the WHO guidelines".
Kumar B, Thakur V, Narang T, et al. PLoS neglected tropical diseases. 2020; 14 (6) : e0008169.
Download PDF

A study of household contacts of persons affected by leprosy with a high bacterial index
Kumar S, Kumar A, Govindharaj P. Leprosy Review. 2020;
Read more

Health-related quality of life associated with erythema nodosum leprosum in Purulia, West Bengal, India
Darlong J, Govindharaj P, Mahato B, et al. Leprosy Review. 2020; 91 (1) : 100-107.
Read more

Perspectives for leprosy control and elimination
Ignotti E, Steinmann P. Cadernos de Saúde Pública. FapUNIFESP (SciELO). 2020;
Download PDF

Epidemiological profile and severity of erythema nodosum leprosum in Brazil: a cross-sectional study.
de Melo C, de Sá B, Costa F, et al. International journal of dermatology. 2020; 59 (7) : 856-861.
Read more

Disability progression among leprosy patients released from treatment: a survival analysis
Santos A, Silva P, Steinmann P, et al. Infectious diseases of poverty. 2020; 9 (1) : 53. 
Download PDF

Prevention of Disability in Children Living with Leprosy-Positive Parents: A Case Report
Wardhani RK, Harini M, Wahyuni LK, et al. Journal of Disability Studies. 2020; 6 (1) : 33-35.
Download PDF

COVID-19 in humanitarian contexts: no excuses to leave persons with disabilities behind!
Handicap International . Handicap International. 2020;
Download PDF

Health technologies for self-care promotion in patients with leprosy: exploring scientific evidence
Cavalcante JL, Xavier SPL, Cabral JFF, et al. Revista Baiana de Enfermagem
. Revista Baiana de Enfermagem. 2020
Download PDF

Profile of Defaulters and Pattern of Treatment Default among Leprosy Patients at a Tertiary Care Hospital: A 10‑Year Analysis
Mushtaq S, Dogra D, Faizi N, et al. Indian Dermatology Online Journal. 2020; 11 (3) : 355-360.
Download PDF

Primary care quality and its effects on leprosy monitoring indicators.
Vieira N, Martínez-Riera J, Lana F. Revista brasileira de enfermagem. 2020; 73 (4) : e20190038.
Download PDF

Analysis of HLA-G protein expression in leprosy.
da Silva C, Sampaio L, Costa M, et al. Immunogenetics. 2020;
Read more

Genotyping of Mycobacterium leprae for understanding the distribution and transmission of leprosy in endemic provinces of China.
Chokkakula S, Shui T, Jiang H, et al. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2020;
Download PDF

Real-time PCR-based quantitation of viable Mycobacterium leprae strain from clinical samples and environmental sources and its genotype in multi-case leprosy families of India.
Singh V, Turankar R, Goel A. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2020;
Read more

Population Genomics of Mycobacterium leprae Reveals a New Genotype in Madagascar and the Comoros.
Avanzi C, Lécorché E, Rakotomalala F, et al. Frontiers in microbiology. 2020;
Download PDF

A Clinical and Histopathological Correlation among Leprosy Patients (in this Post Elimination Era) Attending Tertiary Referral Centre
Thombare MM, Kote R, Gugle A, et al. MVP Journal of Medical Sciences. Informatics Publishing Limited. 2019; 6 (2) : 103-108.
Download PDF

The Correlation of Semmes–Weinstein Monofilament Test with the Level of P-75 Neurotrophin as Marker of Nerve Damage in Leprosy
Widasmara D, Panjarwanto DA, Sananta P. Clinical, Cosmetic and Investigational Dermatology. Informa UK Limited.
Download PDF

Study of TNF-α, IFN-γ, TGF-β, IL-6, and IL-10 gene polymorphism in individuals from the leprosy endemic area in the Brazilian Amazon
dos Santos EC, Machado RLD, Paz JL, et al. Meta Gene. Elsevier BV. 2020
Read more

Temporal trends and spatial distribution of leprosy-related mortality in the state of Tocantins, Brazil, 2000-2015.
Monteiro L, Martins-Melo F, Pires B. Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil. 2020; 29 (3) : e2018336.
Download PDF

Leprosy physical disabilities in the 100 Million Brazilian Cohort
Sanchez MN, Nery JS, Pescarini JM, et al. Research Square. 2020
Download PDF

Activity limitation and social participation restriction of people with leprosy: a cross-sectional analysis of magnitude and associated factors in a hyperendemic municipality in the state of Piauí, Brazil, 2001-2014.
Nascimento D, Ramos A, de Araújo O, et al. Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil. 2020; 29 (3) : e2019543.
Download PDF

Difference in size of leprosy pedis ulcer injury before and after therapy at leprosy hospital Donorejo, Jepara Regency
Kirana PW, Muslimin M, Nugroho TW, et al. DIPONEGORO MEDICAL JOURNAL. 2020; 9 (4) : 357-365.
Download PDF

Are we witnessing a paradigm shift in leprosy: Two atypical presentations of histoid hansen's disease.
Pathania V, Singh J, Sinha A, et al. International journal of mycobacteriology. 2020; 9 (1) : 103-106.
Download PDF

Greater Auricular Neuropathy in Hansen's Disease.
Sharma S, Kulkarni A, Sharma V. The American journal of tropical medicine and hygiene. 2019; 101 (4) : 730-731.
Download PDF

Clinicobacteriological evaluation of leprosy patients with 1-5 skin lesions.
Ansari A, Saxena K, Singh K, et al. International journal of mycobacteriology. 2020; 9 (2) : 209-211.
Download PDF

Late leprosy reaction presenting as erythema multiforme-like erythema nodosum leprosum with underlying rifampicin resistance and its potential implications.
Sardana K, Kulhari A, Mathachan S, et al. International journal of mycobacteriology. 2020; 9 (2) : 226-228.
Download PDF

Leprosy Nephropathy
Antunes VVH, Barros E, Martins AMC, et al. Tropical Nephrology. Springer International Publishing. 2020;
Read more

Leprosy Reactions
Walker SL. The International Textbook of Leprosy. The International textbook of leprosy. 2020
Download PDF

Bulletin de l'ALLF - Revue francophone d'information sur la lèpre et l'ulcère de Buruli.
Association des Léprologues de Langue Française. 2020;
Read more

WHO goodwill ambassador's newsletter for the elimination of leprosy.
Sasakawa Health Foundation. 2020;
Download PDF

 


 

 


 

Journals & Newsletters

 


 

Hansenologia Internationalis: http://www.ilsl.br/revista/atual.php

Indian Journal of Leprosy: http://www.ijl.org.in/index.html

Leprosy Review: https://leprosyreview.org/
Leprosy Review Repository (1928-2001): http://leprev.ilsl.br/arquivo.php

Revista de Leprología:
http://www.leprosy-information.org/resource/revista-de-leprologia

WHO Goodwill Ambassador's Newsletter for the elimination of leprosy:
https://www.shf.or.jp/information/g/ambassador?lang=en

 


 

Websites & Services

 


 

ALLF - Association of French-speaking leprologists - the official webpage of the Association of French-speaking leprologists
https://allf.medicalistes.fr/

LML - Leprosy Mailing List - a free moderated email list that allows all persons interested in this theme to share ideas, information, experiences, and questions.
https://groups.google.com/forum/#!forum/leprosymailinglist

InfoNTD - Information on cross-cutting issues in Neglected Tropical Diseases (NTDs)
https://www.infontd.org/




 

 


 

GDPR & the Infolep newsletter

 


 

New EU data protection regulations came into force on 25 May 2018. We have been reviewing our practices with regard to the GDPR, including our privacy statement and mailing list. Infolep sends out monthly e-mails to its subscribers with an overview of recent publications on leprosy. The purpose of this activity is to keep subscribers up to date. Infolep will only process the data we have (names, email addresses) for the purpose of sending you the newsletter. We take your security seriously and will never share your contact details with anyone else. We hope the content from the Infolep newsletter is useful to you, but you can update your preferences or unsubscribe from this list at any time.



 

 


 

Disclaimer

 


 

Some articles contain stigmatised wording. Please note that Infolep disapproves any stigmatising language. However, we aim to enable access to all relevant publications and want to emphazize that we are not responsible for the content of these publications. We inform journals when we notice stigmatising language in one of their articles and propose alternative wording.

 


 

 



LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com

--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion on the web, visit https://groups.google.com/d/msgid/leprosymailinglist/77684148-49fd-4f25-af03-ea7375f52190o%40googlegroups.com.